Celgene International Sárl (CELG) Release: REVLIMID(R) Granted Approval for Treatment of Relapsed or Refractory Multiple Myeloma in Japan
6/25/2010 10:31:39 AM
BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (NASDAQ: CELG) announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan’s Ministry of Health, Labour and Welfare (MHLW) for use in combination with dexamethasone as a treatment for patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy. This marketing authorization represents the first regulatory approval of REVLIMID in Japan.
comments powered by